

RESEARCH ARTICLE

Effect of cellular polyanion mimetics on tau peptide aggregation

Tania Ismail | Mathumai Kanapathipillai 

Department of Mechanical Engineering,
University of Michigan-Dearborn, Dearborn,
MI 48128, USA

Correspondence

Mathumai Kanapathipillai, University of
Michigan-Dearborn, Department of
Mechanical Engineering, Dearborn, MI 48128,
USA.

Email: mathumai@umich.edu

Funding information

University of Michigan Dearborn

Tau protein aggregation is believed to be one of the key drivers of Alzheimer's disease. The two hexapeptide amino acid sequences $^{306}\text{VQIVYK}^{311}$ and $^{275}\text{VQIINK}^{280}$ of the tau protein are responsible for aggregation, and subsequent functional loss leading to Alzheimer's progression. Hence, it is important to understand the factors that promote the self-aggregation of this tau peptide fragments. Cellular microenvironmental polyanions are known to play a major role in tau protein aggregation and loss of function. Previous studies mainly focused on the effect of heparin and heparan sulfate solution on the full tau protein aggregation. Here, we study the effect of cellular polyanion mimetics, glycosaminoglycans (GAGs) in solution and on surface to mimic intracellular and extracellular conditions, and cellular RNA on the aggregation of tau hexapeptide $^{306}\text{VQIVYK}^{311}$, and mutant tau peptide $^{273}\text{GKVQIIN_KLDL}^{284}$ found frequently in taupathy. Characterization techniques used for the study include biochemical assays, electron microscopy, and spectroscopy techniques to investigate the aggregation *in vitro*. Results show while all the GAGs in solution form play a role in tau peptides aggregation, heparin, chondroitin sulfate, and dermatan sulfate in particular significantly promote the tau peptides aggregation formation. On the other hand, surface-coated GAGs did not promote significant tau aggregation. As far as cellular RNA is concerned, results show significant increase in tau peptides aggregation and toxicity in neuroblastoma cells. The study on the tau peptides fragments aggregation in the presence of GAGs and cellular RNA could provide novel information on the tau aggregation mechanism and could open ways for developing cellular polyanions modulating therapeutics for treating Alzheimer's disease.

KEYWORDS

aggregation, Alzheimer's, glycosaminoglycans, RNA, tau peptide

1 | INTRODUCTION

Tau protein aggregation and subsequent neurofibrillary tangle formation are major hallmarks of Alzheimer's disease. Recent reports suggest understanding the tau aggregation mechanism could help develop clinically relevant therapies in combating the Alzheimer's disease.^{1,2} Tau protein consists of 441 amino acids with microtubule binding region that contains four repeat peptide units.^{3,4} They are composed of hexapeptide domains, which are believed to be the major drivers of tau pathological assembly. The hexapeptide repeats

$^{306}\text{VQIVYK}^{311}$, and $^{275}\text{VQIINK}^{280}$, of the tau protein have been shown to form inter-tau beta sheets, aggregates, and fibril structures.⁵⁻⁹ The hexapeptide repeats are well studied and hence is widely used as a model to study tau aggregation *in vitro*.

Several factors are known to influence the tau aggregation.^{5,10-12} Among them, polyanions, glycosaminoglycans (GAGs) and their sulfated forms, and cellular RNA have shown to induce Alzheimer's like changes in tau protein and believed to play a major role in tau aggregation.^{13,14} Further, sulfated GAGs have shown to promote tau aggregation and have been found to be present in Alzheimer's disease

affected brain.^{13,15} Hence, it is important to understand the influence of the polyanions on tau aggregation. Previously, it has been shown that GAGs influence the aggregation of amyloid beta peptide (A β ₄₂) aggregation *in vitro*.¹⁶ Also, it has been reported that tau assemble into filaments like morphology in the presence of sulfated heparin,¹⁷ and heparin induced conformational changes in tau protein have been observed.^{18,19} Further, recently NMR studies on tau-glycans interactions have been reported, where it has been shown that 6-O-sulfation in heparin is important for tau interaction.²⁰ In another study, tau peptide fragments aggregation in the presence of heparin has been shown to shift the oligomeric conformation of tau and contribute to the subsequent fibril formation kinetics and morphology of the final aggregates.²¹ However, the effect of other GAG molecules on tau hexapeptides aggregation under intracellular and extracellular mimetic conditions has not been explored in detail. In the extracellular conditions, GAGs are displayed on the extracellular matrix surface, while in the intracellular conditions, they are present in the solution. Given that tau aggregation has been observed both in intracellular and extracellular microenvironment,^{22,23} it is important to test the tau aggregation in the presence of GAGs both in solution and on surface. Further, effect of cellular RNA on the tau peptides aggregation is yet to be explored as well.

Here, in this paper, we study the effect of GAG molecules heparin (Hep), heparan sulfate (HepS), dermatan sulfate (DS), chondroitin sulfate (CS), and hyaluronic acid (HA) in solution and on surface, and cellular RNA, on the aggregation of tau hexapeptide domain³⁰⁶VQIVYK³¹¹ (Tau V) segment from the microtubule binding region of tau protein, and the Δ K280 mutant peptide fragment²⁷³GKVQIIN_KLDL²⁸⁴ (Tau N) widely found in taupathy. The aggregation of the peptides in the presence of polyanions was studied utilizing the biochemical, microscopy, and spectroscopy characterization methods, thioflavin S fluorescence assay, transmission electron microscopy (TEM), atomic force microscopy (AFM), turbidity, dynamic light scattering (DLS), and cell toxicity assay. The results show that the heparin, chondroitin sulfate, and dermatan sulfate in solution significantly promote tau peptides aggregation and fibril formation, while surface-coated GAGs did not promote significant aggregation. Further, cellular RNA significantly promoted the peptides aggregation as well. The study demonstrates for the first time the effect of cellular polyanion mimetics on tau peptides aggregation and hence could provide added information on the role of polyanions in tau aggregation.

2 | MATERIALS AND METHODS

2.1 | Materials

Tau peptides (Ac-VQIVYK-NH₂, Ac-GKVQIINKLDL-NH₂) were custom synthesized from Genscript. Low molecular weight heparin, heparan sulfate (GAG-HS01), dermatan sulfate (GAG-DS01), and hyaluronic acid (HA93) were purchased from Galen Laboratory Supplies. Chondroitin sulfate (C4384), all other chemicals, and reagents were purchased from Sigma Aldrich. Heparin/GAG binding plates (SKU: H/G plates) were purchased from Galen Laboratory Supplies, and the PureLink RNA mini kit was purchased from Thermo Fisher Scientific.

2.2 | ThS fluorescence measurements

First stock solutions of tau peptides (1 mM) and GAGs (1 mM) were prepared by dissolving in deionized water. ThS was freshly prepared at a concentration of 0.5 mg/mL in 20 mM MOPS buffer, pH 7. For the ThS measurement, 10 μ L of peptide was dissolved in 2.5- μ L GAG stock solution, 10- μ L ThS, and MOPS buffer to make the final 100- μ L working solution. In the case of RNA, 0.25 and 0.5 ng/mL of final RNA concentrations were used with 100 μ M of final tau peptide concentrations. A M3 spectramax spectrophotometer was used to measure the ThS fluorescence at 440/490 nm, excitation and emission. Aggregation kinetic measurements were performed every 2 minutes for 30 minutes, in 96 black well plates. At least three independent experiments were carried out, and the average readings were obtained.

2.3 | DLS

A Malvern zetasizer instrument in the lab was used to measure the size of the aggregation of the peptides with GAGs. Samples were prepared under similar conditions used for the ThS measurements, but without the ThS, and the size measurements were performed. Three independent size measurement experiments were performed for each GAG condition.

2.4 | Turbidity measurements

The peptides aggregation was measured by the turbidity of the samples at 400 nm. Samples were prepared under similar conditions used for the ThS study, but without the ThS, and the turbidity measurements were performed using a spectramax M3 spectrophotometer in the lab. Three independent size measurement experiments were performed for each GAG condition.

2.5 | TEM

Transmission electron microscopy images were obtained using the JEOL JSM 1400 TEM at UM-Ann arbor electron microscope facility. The peptides were aggregated with GAGs for 1 hour, spotted on holy carbon copper grids, and then stained with 1% uranyl formate.

2.6 | Cell toxicity assay

The toxicity of tau peptides aggregates with GAGs on human neuroblastoma SH-SY5Y cells was studied by the XTT assay. Cells were obtained from American Type Culture Collection (ATCC) and cultured according to the protocol. For the study, 2×10^4 cells/well were cultured in 96 well plates overnight. Peptides (32 μ M) with or without GAGs of concentrations (8 μ M) were aggregated for 24 hours and subsequently incubated for 48 hours. For RNA induced toxicity, peptides (16 μ M) with or without RNA of 0.8 ng/mL were used. XTT assay was measured at 470 nm, and the viability was determined according to manufacturer's protocol.

2.7 | GAGs surface coating and aggregation assays

To study the influence of surface-coated GAGs on peptide aggregation, first GAGs were coated on GAGs binding plates. For GAGs binding, 100- μ L solution of 0.01 M PBS containing 25 μ M of GAGs (Hep, CS, DS, HepS, and HA) was added to a GAGs binding plate (Heparin/GAG binding plates (SKU: H/G plates) and incubated at room temperature according to manufacturer's protocol. After 24 hours, the PBS/GAGs solution was aspirated, and the wells were washed three times with PBS buffer. For aggregation studies on GAGs coated plates, 15 μ L of 1 mM Tau N, 15- μ L ThS (0.5 mg/mL), and 120- μ L MOPS (20 mM) solution was added into each well. The turbidity of the peptide aggregates was measured at 400-nm wavelength after 30-minute incubation. The morphology of the aggregation was characterized by AFM.

2.8 | RNA extraction

Human brain microvascular endothelial cells (hBMVEC) were cultured at a density of $\leq 5 \times 10^6$ cells/mL. PureLink RNA mini kit was used to extract the RNA from the cells, according to the manufacturer's protocol. Using the Spectra-Drop protocol in spectramax M3 spectrophotometer, the absorbance was measured from 230 to 280 nm. Then, using the measured optical density at 260 nm and the provided standard curve (optical density 260 nm vs concentration), the concentration of RNA was obtained. The purified RNA was stored at -80°C until used for the aggregation studies.

2.9 | AFM

Hitachi AFM 5100 N was used to obtain the AFM images for tau peptides samples with GAGs and RNA. For preparation, 2 μ L of the aggregated sample solutions was spotted on freshly cleaved mica, and kept to dry, and washed it with water to remove salt, and dried again before imaging. AFM tips (Applied Nanostructures Inc.) with an

average resonance frequency of 300 kHz were used to image samples using tapping mode. The length and the width of the cantilever are 125 and 30 μ m, respectively, and the average force constant is 37 N/m.

2.10 | Statistical analysis

Each experiment was conducted three or more times, and they are presented as mean \pm standard error of the mean (SEM). *P*-values were determined from the results of at least three independent experiments. For statistical significance, unpaired *t*-test was used. Each GAG condition were compared with the controls without GAGs. ***P* < 0.01 and **P* < 0.05 are considered as significance.

3 | RESULTS AND DISCUSSION

The goal of the study is to test the influence of polyanions on tau peptides aggregation, subsequent fibril formation, and cellular toxicity. For the GAGs induced aggregation study, peptides to GAGs molar ratios of 4:1 or 20:1 were used, at a constant tau peptide concentration of 100 μ M. The starting molar ratio 4:1 and tau concentration (100 μ M) were chosen as previously reported,^{24,25} while the 20:1 molar ratio was tested to see if the tau peptide:GAGs concentration ratio has an effect on the aggregation. Thioflavin S measurements show that the GAGs influence both Tau V and Tau N peptides aggregation in vitro. The enhanced ThS signal in the presence of GAGs may be due to the presence of aggregates amount or due to the differences in aggregates structure. Increased thioflavin signal of the peptides was observed in the presence of chondroitin sulfate, heparin, and dermatan sulfate (Figure 1A,B). Heparan sulfate and hyaluronan on the other hand exhibited minimal thioflavin S fluorescence. At both 4:1 and 20:1 molar ratios, chondroitin sulfate seems to exhibit




FIGURE 1 A, Tau V peptide (100 μ M) aggregation kinetics was studied with GAGs (25 μ M). B, Tau N peptide (100 μ M) aggregation kinetics was studied with GAGs (25 μ M). ThS fluorescence shows the aggregation is influenced by the presence of glycosaminoglycan used. Experiments were repeated three times ($n = 3$) and averaged. Here, Tau V—VQIVYK; TauN—GKVQIINKLDL; CS—chondroitin sulfate; Hep—heparin; DS—dermatan sulfate; HepS—heparan sulfate; HA—hyaluronic acid; ThS—thioflavin S

enhanced thioflavin S binding of Tau V peptide (Figure 1A, Figure S1A). Tau N ThS binding is enhanced in the presence of chondroitin sulfate at lower GAG molar ratios (20:1) (Figure S1B), while at higher GAG molar ratios (4:1), heparin seems to have more influence on the thioflavin S binding (Figure 1B). This may be due to the influence of heparin concentration on tau interaction whereas chondroitin sulfate does not seem to influence aggregation at higher molar ratio. Also, it is important to note that heparin exhibited significant aggregation (P -value <0.01) compared with the sulfated form of heparin revealed by t -test for the measurements (heparin vs heparin sulfate) performed for the ThS kinetics.

Dynamic light scattering and turbidity measurements were then used to measure the size distribution, and turbidity of the peptide aggregates, with and without GAGs. As can be seen from Figure 2A, chondroitin sulfate, heparin, and dermatan sulfate-treated Tau N peptides exhibited larger sizes, indicating the influence on aggregation or fibrillar structures; however, significant increase in size was observed with chondroitin sulfate treated samples only. Similarly, as for the Tau V peptide aggregation size, although increase in the size for all the GAG-treated peptides was observed compared with Tau V peptide alone, chondroitin sulfate-treated peptide samples exhibited significant increase in aggregation size (Figure 2B). It is also important to point out that the DLS measurements may be influenced by the conformational heterogeneity and the size of the aggregates and hence is an approximate method to predict the aggregates size. The turbidity measurements reveal significant turbidity with chondroitin sulfate,

heparin, heparan sulfate, and dermatan sulfate-treated peptides compared with Tau V and Tau N peptides alone (Figure 3). Hyaluronic acid, on the other hand, exhibited no significant turbidity with both peptides. However, DLS measurements revealed that TauV samples treated with hyaluronic acid showed larger size aggregates (Figure 2 B); this may be due to the formation of few globular aggregates, which may have contributed to larger size, but not significant turbidity.

Next, we tested the morphology of the Tau N and TauV aggregates by TEM (Figures 4 and 5). Images reveal that the Tau N peptides treated with heparin, and chondroitin sulfate exhibited significant amount of fibril like structures (Figure 4), in agreement with the ThS measurements. Dermatan sulfate-treated peptides exhibited aggregates like morphology. Also, in agreement with the ThS measurements, the TEM images of heparan sulfate and hyaluronic acid-treated samples showed no significant aggregation compared with other GAGs-treated samples. Similar observations were found with Tau V aggregated samples (Figure 5), although the amount of aggregation/fibrillar morphology seems to be less compared with Tau N aggregates. This is in agreement with ThS measurement, where higher fluorescence intensities were observed with Tau N samples compared with Tau V samples.

Next, we tested whether aggregation or fibrillar morphologies were observed under extracellular mimetic conditions of GAGs. For this, GAGs were coated on special GAGs binding plates, and then Tau N peptides solutions were subsequently incubated on the surface to allow aggregation. As can be seen from AFM images in Figure S2 A,




FIGURE 2 A. (i). Dynamic light scattering measurements of the Tau N peptide (100 μM) aggregates with GAGs (25 μM). (ii) Tau V peptide (100 μM) aggregation with and without GAGs (25 μM), assessed by turbidity measurements. The average sizes of each peptide with and without GAGs are tabulated on the right for three experiments. * $P < 0.05$. Data are expressed as mean ± SEM




FIGURE 3 (i). Turbidity measurements of the Tau N peptide (100 μM) aggregates with GAGs (25 μM). (ii) Tau V peptide (100 μM) aggregation with and without GAGs (25 μM), assessed by turbidity measurements. * $P < 0.05$. Experiments were performed in triplicates and data are expressed as mean \pm SEM




FIGURE 4 TEM images of Tau N (100 μM) peptide aggregation in the presence of GAGs (25 μM). The aggregates were made in MOPS buffer at 37°C, and the samples were spotted on holy carbon grids and negatively stained with 1% uranyl formate prior to imaging. Scale bar 1 μm

all the GAGs exposed peptides showed aggregates like morphology. However, the amount of aggregates seems to be not significant among the GAGs treated and non-treated samples. To further confirm this, we did turbidity measurements. TauN peptide buffer solutions were incubated on GAGs coated plates and allowed to aggregate. After 30 minutes, the supernatant of the samples were taken, and turbidity measurements were performed. As can be seen from the turbidity study shown in Figure S2 B, there is no significant difference among different GAGs treatment compared with untreated GAGs. However, among the GAGs, chondroitin sulfate treated samples exhibited more aggregation/fibril formation, revealed from both AFM and turbidity. Overall, the data suggests that the intracellular GAGs

may have a major role in tau aggregation compared with extracellular GAGs.

To assess the toxicity effects of GAGs on tau peptide aggregation, we performed cellular toxicity studies of Tau N and Tau V aggregated samples in the presence of GAGs. For the study, we used SH-SY5Y human neuroblastoma cells, that is widely used as a model cell line in neurodegenerative disease studies to assess the toxicity effects.²⁶ Cells were cultured in 96 well plates and incubated with Tau peptides and GAGs solution for 48 hours, and XTT assay was performed to assess the cell viability. As can be seen from Figure 6, all the samples treated with GAGs in solution exhibited toxicity effects. While dermatan sulfate-treated samples showed a slight increase in toxicity,




FIGURE 5 TEM images of Tau V (100 μM) peptide aggregation in the presence of GAGs (25 μM). The samples were aggregated in MOPS buffer at 37°C, and TEM images were obtained to assess the morphology using the similar procedure used for Tau N samples. Scale bar 1 μm




FIGURE 6 Toxicity effect of Tau peptides aggregates with GAGs on SH-SY5Y cells. A, Tau N with GAGs; B, Tau V with GAGs. * $P < 0.05$. Data are expressed as mean \pm SEM, for three experiments

statistically it is not significantly different from other GAGs-treated samples. The enhanced toxicity in the presence of dermatan sulfate may be due to its influence on the formation of tau peptides aggregates like morphology, compared with fibrillar structures as observed from the TEM and AFM images. In addition, the peptides alone also show some toxicity effects, may be due to the influence of extracellular GAGs, deposited by the cells. To confirm the toxicity effects are due to the peptides aggregation and not due to the GAGs itself, we performed the toxicity studies with GAGs only. GAGs alone in solution exhibited no significant toxicity (Figure S3). Polyanions including heparin have shown to promote tau and tau peptide aggregation by binding to the microtubule hexapeptide regions and with the positively charged lysine and histidine amino acid chains.¹² GAGs, which are polyanionic, seem to promote tau aggregation in a similar manner and subsequently exhibit toxic effects on the cells.

As a next step, we tested the role of cellular RNA on Tau N and Tau V peptides aggregation. For the study, we used 0.25 and 0.5 ng/ml of cellular RNA with 100 μM of peptide final concentrations. Both peptides showed enhanced aggregation in the presence of RNA, observed from increase in ThS fluorescence (Figure 7A,B). To determine whether it has similar aggregation kinetics like GAGs, we calculated the rate constants of TauN and Tau V in the presence of chondroitin sulfate, heparin, and RNA. The ThS curves were fitted using four-parameter sigmoidal curve using Matlab with the following equation $y = y_0 + \frac{a}{1 + e^{-(x-x_0)/b}}$; here, y_0 —initial ThS fluorescence, x_0 —50% of the maximum fluorescence value, a —maximal fluorescence value, and y and x are the ThS fluorescence, and time, as previously reported in literature to determine protein aggregation kinetics.²⁷ As can be seen from Table 1, the RNA and GAGs influence




FIGURE 7 A, Tau N peptide (100 μ M) aggregation kinetics was studied with RNA concentrations of 0.25 and 0.5 ng/mL. B, Tau V peptide (100 μ M) aggregation kinetics was studied with RNA concentrations of 0.25 and 0.5 ng/mL. ThS fluorescence reveals the Tau V aggregation is significantly influenced by the presence of RNA. C, AFM images of Tau N and Tau V peptide aggregation in the presence of RNA

TABLE 1 Apparent rate constant of tau peptides aggregation with GAGs and RNA

Kapp (min^{-1})					
TauV:CS	TauV:Hep	TauV:RNA	TauN:CS	TauN:Hep	TauN:RNA
1	0.45	0.625	0.06	0.15	0.15

Note: Here Tau V—100 μ M; CS, Hep—25 μ M; RNA—0.5 ng/mL. Tau V and Tau N alone exhibited negligible Kapp values, indicating very slow kinetics in the absence of GAGs or RNA, and hence not reported in the table.

on the aggregation kinetics is comparable within the peptides. However, Tau V in the presence of GAGs and RNA showed faster kinetics compared with Tau N samples. This is further evidenced by AFM imaging where Tau V treated with RNA exhibited more aggregates compared with Tau N in general (Figure 7C). From the images, Tau N seems to drive more fibril like structures, while Tau V forms more globular aggregates. Finally, the RNA mediated Tau V and Tau N aggregates toxicity was assessed in SH-SY5Y cells. Tau V exhibited significant toxicity, whereas Tau N did not exhibit toxicity at the tested concentrations (Figure 8). This may be due to the significant Tau V aggregation formation in the presence of RNA (Figure 7).

Glycosaminoglycans have shown to play a key role in Alzheimer's disease. A recent study reveals that increased evidence suggest that N-glycans may play an important role in Alzheimer's disease.²⁸ In another study, it is stated that GAGs have a scaffolding role on amyloidogenic proteins.²⁹ Further, it has been reported that GAG heparin, which is anionic in nature, is believed to play a key role in the tau




FIGURE 8 Toxicity effect of Tau peptides aggregates in the presence of RNA on SH-SY5Y cells. Tau N and Tau V at 16- μ M concentrations were incubated with and without 0.8 ng/mL RNA, and toxicity was performed after 48 h. * $P < 0.05$ indicates significance, determined from three independent experiments, and data are expressed as mean \pm SEM

aggregation by interacting with the microtubule binding region.^{13,18} RNA is also known to play a key role in tau aggregation. Kampers et al has shown that in the presence of bovine or yeast RNA, the tau was assembled into paired helical filaments.¹⁴ Here, we show that GAGs and human brain endothelial cellular RNA in solution have the

capability to influence the tau peptides aggregation, fibrillization, and toxicity in vitro. As far as GAGs are concerned, chondroitin sulfate, dermatan sulfate, and heparin seem to influence the peptide aggregation more compared with other GAGs. Although it has been reported that the sulfated form of heparin is found in the amyloid plaques, it did not promote significant aggregation of tau peptides under in vitro conditions. Hyaluronic acid showed the least aggregation promoting effects among the GAGs studied. Further, the GAGs in solution seem to have more influence on the aggregation compared with the surface-coated GAGs. Cellular RNA in few ng/mL concentrations exhibited significant aggregation and toxicity of Tau V peptides that are known to be a key driver in tau aggregation.⁵ Hence, cellular RNA could have potential influence in intracellular tau assembly.

4 | CONCLUSION

From this proof of concept study, we show that the polyanions influence the microtubule tau peptide, and mutant peptide aggregation under in vitro conditions. The kind of GAG, and the sulfate modifications, and the physical representation also seem to influence the aggregation mechanism. The studies also show that cellular RNA may play a significant role in tau aggregation and toxicity. This study could open further opportunities for the investigation of polyanions associated tau aggregation mechanisms and therapeutic interventions.

ACKNOWLEDGEMENT

We would like to thank the University of Michigan Dearborn, Department of Mechanical Engineering, and the College of Engineering and Computer Science for funding. We would like to thank the University of Michigan Microscope and Imaging (MIL) facility for the use of TEM microscope.

ORCID

Mathumai Kanapathipillai  <http://orcid.org/0000-0001-8748-6848>

REFERENCES

- Giacobini E, Gold G. Alzheimer disease therapy—moving from amyloid-beta to tau. *Nat Rev Neurol*. 2013;9(12):677-686.
- Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochem Pharmacol*. 2014;88(4):529-539.
- Avila J, Jimenez JS, Sayas CL, et al. Tau structures. *Front Aging Neurosci*. 2016;8:262.
- Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. *Curr Alzheimer Res*. 2010;7(8):656-664.
- von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. *Biochim Biophys Acta*. 2005;1739(2-3):158-166.
- Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer's disease. *Brain Pathol*. 2007;17(1):83-90.
- Li W, Lee VM. Characterization of two VQIXXK motifs for tau fibrillization in vitro. *Biochemistry*. 2006;45(51):15692-15701.
- Goux WJ, Kopplin L, Nguyen AD, et al. The formation of straight and twisted filaments from short tau peptides. *J Biol Chem*. 2004;279(26):26868-26875.
- Ganguly P, Do TD, Larini L, et al. Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3. *J Phys Chem B*. 2015;119(13):4582-4593.
- Boutajangout A, Wisniewski T. Tau-based therapeutic approaches for Alzheimer's disease—a mini-review. *Gerontology*. 2014;60(5):381-385.
- Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, Trojanowski JQ. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. *Exp Neurol*. 2010;223(2):304-310.
- Mukrasch MD, Biernat J, von Bergen M, Griesinger C, Mandelkow E, Zweckstetter M. Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. *J Biol Chem*. 2005;280(26):24978-24986.
- Papy-Garcia D, Christophe M, Huynh MB, et al. Glycosaminoglycans, protein aggregation and neurodegeneration. *Curr Protein Pept Sci*. 2011;12(3):258-268.
- Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. *FEBS Lett*. 1996;399(3):344-349.
- Ariga T, Miyatake T, Yu RK. Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies—a review. *J Neurosci Res*. 2010;88(11):2303-2315.
- McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. *Eur J Biochem*. 1999;266(3):1101-1110.
- Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. *Nature*. 1996;383(6600):550-553.
- Paudel HK, Li W. Heparin-induced conformational change in microtubule-associated protein tau as detected by chemical cross-linking and phosphopeptide mapping. *J Biol Chem*. 1999;274(12):8029-8038.
- Ramachandran G, Udgaonkar JB. Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by tau protein. *J Biol Chem*. 2011;286(45):38948-38959.
- Zhao J, Huvent I, Lippens G, et al. Glycan determinants of heparin-tau interaction. *Biophys J*. 2017;112(5):921-932.
- Larini L, Gessel MM, LaPointe NE, et al. Initiation of assembly of tau(273-284) and its DeltaK280 mutant: an experimental and computational study. *Phys Chem Chem Phys*. 2013;15(23):8916-8928.
- Evans LD, Wassmer T, Fraser G, et al. Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. *Cell Rep*. 2018;22(13):3612-3624.
- Avila J. Intracellular and extracellular tau. *Front Neurosci*. 2010;4:49.
- Eschmann NA, Do TD, LaPointe NE, et al. Tau aggregation propensity engrained in its solution state. *J Phys Chem B*. 2015;119(45):14421-14432.
- Nadimidla K, Ismail T, Kanapathipillai M. Tau peptides and tau mutant protein aggregation inhibition by cationic polyethyleneimine and polyarginine. *Biopolymers*. 2017;107(9).
- Schlachetzki JC, Saliba SW, Oliveira AC. Studying neurodegenerative diseases in culture models. *Rev Bras Psiquiatr*. 2013;35(Suppl 2):S92-S100.
- Arora A, Ha C, Park CB. Inhibition of insulin amyloid formation by small stress molecules. *FEBS Lett*. 2004;564(1-2):121-125.
- Kizuka Y, Kitazume S, Taniguchi N. N-glycan and Alzheimer's disease. *Biochim Biophys Acta*. 2017;1861(10):2447-2454.
- Aguilera JJ, Zhang F, Beaudet JM, Linhardt RJ, Colon W. Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid a. *Biochimie*. 2014;104:70-80.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Ismail T, Kanapathipillai M. Effect of cellular polyanion mimetics on tau peptide aggregation. *J Pep Sci.* 2018;24:e3125. <https://doi.org/10.1002/psc.3125>